推薦產品
形狀
powder
包裝
pkg of 1 × 1 g (890810P-1g)
pkg of 1 × 200 mg (890810P-200mg)
pkg of 1 × 25 mg (890810P-25mg)
pkg of 1 × 500 mg (890810P-500mg)
製造商／商標名
Avanti Research™ - A Croda Brand
應用
vaccine development
脂質類型
cationic lipids
transfection
運輸包裝
dry ice
儲存溫度
−20°C
SMILES 字串
CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]
InChI
1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1
InChI 密鑰
PSLWZOIUBRXAQW-UHFFFAOYSA-M
一般說明
18:0 DDAB是阳离子脂质和季铵盐。与可电离的脂质不同，烃尾巴是饱和的。
應用
18:0 DDAB适合制备脂质纳米颗粒。它还可用作佐剂，与单磷酸脂A（MPL）联合用于免疫小鼠。
生化／生理作用
18:0 DDAB是一种表面活性分子，可用作诱导全身免疫反应的佐剂。无毒。
包裝
20 mL透明玻璃螺旋盖样品瓶（890810P-1g）
20 mL透明玻璃螺旋盖样品瓶（890810P-500mg）
5 mL棕色玻璃螺旋盖样品瓶（890810P-200mg）
5 mL棕色玻璃螺旋盖样品瓶（890810P-25mg）
其他說明
仅供研发使用。& 不可用于药物、家庭或其他用途。
法律資訊
Avanti Research is a trademark of Avanti Polar Lipids, LLC
也與該產品經常一起購買
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
客戶也查看了
Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens
Klinguer C, et al.
Vaccine, 19(30), 4236-4244 (2001)
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel S, et al.
J. Controlled Release, 303, 91-100 (2019)
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務